Summary Intact SWA II antibody was evaluated as a potential radioimmunotherapeutic agent against small cell lung cancer xenografts in a nude mouse model system. I3II-labelled SWAII was given either in a single injection regimen (I x 300 #tCi) or as a multiple injection regimen achieving a total of 900 pCi (3 x 300 pCi with a 2 week interval between injections). Treatment of both small (mean volume approximately 0.2 cm3) and large (mean volume approximately 1.0 cm3) established xenografts resulted in significant anti-tumour effects and, in the case of the fractionated protocol, the failure of the xenografts to regrow within the period of observation (84 days). Xenograft histology following radioimmunotherapy showed large areas of necrosis, fibrosis and very few residual cells of SCLC origin.
Small cell cancer of the lung (SCLC) is a highly chemo-and radiosensitive disease for which the long term prognosis remains poor. Following initial chemotherapy, a fatal relapse caused by a re-emergent chemoresistant form of the disease occurs in most patients (De Leij et al., 1987) . Between first treatment and relapse, the disease exists as widely spread small cellular foci which may retain their radiosensitivity. In an effort to develop new anti-SCLC diagnostic and therapeutic agents we have generated a panel of murine monoclonal antibodies directed against target SW2 cells of SCLC origin. We describe here a therapeutic study with the IgG2a antibody SWAl (Smith et al., 1989) in a nude mouse model system. The successful application of radioimmunotherapy (RIT) for the treatment of malignant conditions depends upon many contributing factors of which the actual disease chosen for therapy is among the most important. Malignant disease such as SCLC, which may occur dispersed throughout the body as relatively small and radiosensitive foci, fulfils the conditions of a suitable target tumour as described by Dykes et al. (1987) . The requirement for new treatment modalities is underlined by the high mortality of the disease when treated with current therapeutic protocols (de Vita et al., 1985; Carney, 1987 
Monoclonal antibody
Our procedure for antibody generation has been previously described (Stahel et al., 1985 In vitro immunoreactivity To determine accurately the biological activity of radiolabelled SWA 11 intended for use in RIT studies, SW2 cells were washed x 3 in PBS (with 5% non-fat milk, 0.05% azide) and varying cell numbers (from 0.625 x 106 to 107) were then incubated for 2 h at 4°C with a fixed amount of radiolabelled antibody. After washing as above the activity in the cell pellet was counted. The number of counts remaining unbound were plotted against the reciprocal of the cell number so that the intercept on the y axis indicates the theoretical unreactive fraction. The difference between the input and the estimated unreactive fraction (both in c.p.m.) represents the biological activity of the radiolabelled antibody (Trucco & de Petris, 1981) . maintained on pathogen free food and acidified drinking water which were given ad libitum. Xenograft passage was performed by subcutaneous transplantation of 2-3 mm3 pieces of SW2 tumour into 4-6 week old animals under ether anaesthesia.
Radioimmunotherapy studies
In order to minimise the number of animals used in this study the assumption was made that if control materials failed to inhibit the growth of small (around 0.2 cm3) SCLC xenografts then they would also be unable to inhibit the growth of larger more well established xenografts (Sharkey et al., 1987) . In consequence diluent, unlabelled SWAl 1 antibody and 300 IACi '3ll-anti-CEA antibody were administered to mice bearing small SCLC xenografts in equivalent amounts to those used in the single dose therapeutic studies. In the single dose therapy protocol, groups of nude mice bearing established xenografts of mean volume approximately either 0.2 or 1.0 cm3 were injected i.v. with 100 fig  SWA 11 labelled with 300 fiCi "''I. For multiple dose therapy the animals were injected x 3 with 300 jsCi of 131I-SWA 11 with a 2 week interval between injections. Tumour growth rates were then assessed using the formula of Kopper and Steel (1975) . Animal weight loss was also monitored during the experiment and was found to be transient and in no instance more than 20% of initial body weight.
Xenograft histology
At day 84 all animals treated with 3 x 300 gsCi '3'SWA1 1 were killed and residual tumours fixed in 4% formalin solution. Sections were stained with haematoxylin and eosin and then compared with tumour sections taken from diluent treated control animals.
Results
Resistance to radiolabelling Figure 1 shows the binding of 1311 SWAl 1, labelled over the range of specific activities 2.5-25 mCi mg-', to SW2 cells in a fixed cell radioimmunoassay. Increased specific activity is seen to result in accompanying increase in counts bound to target cells up to an activity of 15 mCi mg-' thereby indicating SWA 11 to retain its biological activity over the indicated range of labelling. Little increase in c.p.m. bound was observed between 15 and 25 mCi mg-' suggesting impairment of immunoreactivity.
In vitro immunoreactivity The iodogen radiolabelling reagent was routinely employed to produce iodinated SWA 1. The biological activity of the labelled antibody intended for use in RIT studies was normally around 65-70% as shown in Figure 2 .
Radioimmunotherapy studies The administration of unlabelled SWAl 1 or 300 fiCi "' Ilabelled anti-CEA control antibody had no significant effect on the growth rate of small (around 0.2 cm3) SCLC xenografts when compared to the diluent control group (Figure  3a) .
In the single injection study the mean starting volumes of the small and large tumour groups were 0.18 ( ± 0.08) and 0.95 ( ± 0.13) cm3 respectively. In the case of small tumours the injection of 300 jiCi 13'1-labelled SWA 11 resulted in marked tumour shrinkage and no evidence of regrowth until after day 34 post-injection. Rapid growth then resumed up to day 70 when the animals were killed. Large tumours were less susceptible to treatment showing no change in volume up to day 14 followed by resumed rapid growth (see Figure 3b ).
At the start of the multiple dose protocol mean tumour volumes were 0.15 ( ± 0.07) cm3 and 1.3 ( ± 0.10) cm3 for the small and large tumour groups respectively. The small tumour group shrank to a minimum volume by day 49 and remained static until termination of the experiment at day 84.
The large tumour group shows a fall in mean tumour volume to a minimum at day 56 (i.e. 28 days after the last injection). As in the small tumour group, no evidence of regrowth was observed up to termination of the experiment (Figure 4 ). Reciprocal of (cell number x 10-8) Figure 1 Resistance of SWAl I to radiolabelling procedures. SWA 1I was labelled with 13' I over a range of specific activities from 2.5-25mCimg-' and was then used in a radioimmunoassay against fixed SW2 cells at a concentration determined to give half maximal binding. Reports in the literature of successful radioimmunotherapy of human tumour xenografts are few and restricted to the treatment of xenografts derived from highly radiosensitive tumour types such as neuroblastoma (Cheung et al., 1986) or to model systems in which fractionated protocols have been adopted (Buchegger et al., 1990; Schlom et al., 1990) .
Radioimmunotherapy of SCLC xenografts was originally described by Yoneda et al. (1988) . A single injection of 500 tCi "1'I-labelled regrowth to day 84 of the study. This strategy of giving second and third treatments before an opportunity for tumour regrowth has occurred seems to have strongly enhanced the overall antitumour effect of the '31I-SWA1 1 conjugate as compared to the '3'I-TSF-4 conjugate of Yoneda.
The apparent ablation of well established SCLC xenografts by fractionated radioimmunotherapy is an encouraging result although conclusions as to the efficacy of radiolabelled antibodies in the clinical situation can not be made directly from data obtained in a mouse model system. However, the work presented here confirms the status of SCLC as a prime target for tumour-specific radioimmunotherapy due to its high radiosensitivity and augures well for the eventual application of radioimmunotherapy as part of a combined modality approach to the treatment of SCLC.
